Ikebe M - Search Results

1

Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma.

Teicher BA, Holden SA, Dupuis NP, Kakeji Y, Ikebe M, Emi Y, Goff D. Teicher BA, et al. Among authors: ikebe m. Breast Cancer Res Treat. 1995;36(2):227-36. doi: 10.1007/BF00666043. Breast Cancer Res Treat. 1995. PMID: 8534870

2

Increased efficacy of chemo- and radio-therapy by a hemoglobin solution in the 9L gliosarcoma.

Teicher BA, Dupuis NP, Emi Y, Ikebe M, Kakeji Y, Menon K. Teicher BA, et al. Among authors: ikebe m. In Vivo. 1995 Jan-Feb;9(1):11-8. In Vivo. 1995. PMID: 7669943

3

Influence of an anti-angiogenic treatment on 9L gliosarcoma: oxygenation and response to cytotoxic therapy.

Teicher BA, Holden SA, Ara G, Dupuis NP, Liu F, Yuan J, Ikebe M, Kakeji Y. Teicher BA, et al. Among authors: ikebe m. Int J Cancer. 1995 May 29;61(5):732-7. doi: 10.1002/ijc.2910610523. Int J Cancer. 1995. PMID: 7768649

4

Dynamics of tumor oxygenation, CD31 staining and transforming growth factor-beta levels after treatment with radiation or cyclophosphamide in the rat 13762 mammary carcinoma.

Kakeji Y, Maehara Y, Ikebe M, Teicher BA. Kakeji Y, et al. Among authors: ikebe m. Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1115-23. doi: 10.1016/s0360-3016(96)00573-1. Int J Radiat Oncol Biol Phys. 1997. PMID: 9169821

5

Transforming growth factor-beta 1 overexpression produces drug resistance in vivo: reversal by decorin.

Teicher BA, Ikebe M, Ara G, Keyes SR, Herbst RS. Teicher BA, et al. Among authors: ikebe m. In Vivo. 1997 Nov-Dec;11(6):463-72. In Vivo. 1997. PMID: 9509296

6

Alterations in gene expression between EMT-6 mammary carcinoma monolayers and spheroids identified by differential display.

Ikebe M, Teicher B. Ikebe M, et al. Int J Oncol. 1996 Oct;9(4):629-34. doi: 10.3892/ijo.9.4.629. Int J Oncol. 1996. PMID: 21541562

7

Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer.

Oki E, Baba H, Tokunaga E, Nakamura T, Ueda N, Futatsugi M, Mashino K, Yamamoto M, Ikebe M, Kakeji Y, Maehara Y. Oki E, et al. Among authors: ikebe m. Int J Cancer. 2005 Nov 10;117(3):376-80. doi: 10.1002/ijc.21170. Int J Cancer. 2005. PMID: 15900596 Free article.

8

Phase II Trial of S-1 and Oxaliplatin Plus Cetuximab for Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases (KSCC1002).

Oki E, Emi Y, Miyamoto Y, Kabashima A, Higashi H, Ogata Y, Ikebe M, Saeki H, Tokunaga S, Shirabe K, Beppu T, Uchida S, Takatsuki M, Sakoda M, Eguchi S, Akagi Y, Kakeji Y, Baba H, Natsugoe S, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC). Oki E, et al. Among authors: ikebe m. Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1067-74. doi: 10.1245/s10434-015-4771-1. Epub 2015 Sep 3. Ann Surg Oncol. 2015. PMID: 26334293 Clinical Trial.

9

Salvage esophagectomy after definitive chemoradiotherapy for esophageal cancer.

Oki E, Morita M, Kakeji Y, Ikebe M, Sadanaga N, Egasira A, Nishida K, Koga T, Ohata M, Honboh T, Yamamoto M, Baba H, Maehara Y. Oki E, et al. Among authors: ikebe m. Dis Esophagus. 2007;20(4):301-4. doi: 10.1111/j.1442-2050.2007.00677.x. Dis Esophagus. 2007. PMID: 17617878

10

Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients.

Tokunaga E, Kimura Y, Oki E, Ueda N, Futatsugi M, Mashino K, Yamamoto M, Ikebe M, Kakeji Y, Baba H, Maehara Y. Tokunaga E, et al. Among authors: ikebe m. Int J Cancer. 2006 Jan 15;118(2):284-9. doi: 10.1002/ijc.21358. Int J Cancer. 2006. PMID: 16049961 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

373 results

Search Page